Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027

Caribou Biosciences, Inc.

GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.
Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.
Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.
CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $11.2 million, net income net loss of $148.1 million, EPS $1.59 per share.

Period: the year ended December 31, 2025
Revenue: $11.2 million
Net income: net loss of $148.1 million
EPS: $1.59 per share
Result: reported results

Exact text from the filing

Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported the three months ended December 31, 2025 results: revenue $3.9 million, net income net loss of $26.5 million, EPS $0.28 per share.

Period: the three months ended December 31, 2025
Revenue: $3.9 million
Net income: net loss of $26.5 million
EPS: $0.28 per share
Result: reported results

Exact text from the filing

Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.